fda marty makary - Search News

Order byBest matchMost fresh

FDA Restricts COVID-19 Vaccine Access To High-Risk Groups.

FDA will limit Covid vaccines to people over 65 or at high risk of serious illness, leaders say

will require manufacturers to conduct clinical trials to show whether the vaccines benefit healthy younger adults and children

STAT · 1d

· 1d · on MSN

FDA Changes May Limit COVID Vaccine Access—Drawing Some Criticism. Here’s What We Know

· 20h · on MSN

New FDA chiefs limit Covid-19 shots to elderly, sick

Trump officials set new requirements for COVID vaccines in healthy adults and children

Annual COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.

· 1d

Axios · 1d

New COVID booster rules could limit shots for people under 65

WBAL · 19h

FDA plans to limit COVID shots to those over 65 or with high-risk conditions

13h

FDA Commissioner Makary Cites Real Clear Journal Article At Panel On Talc In The American Food Supply

"Expert Panels with the FDA" are a series of roundtable discussions to provide an open public discourse on the latest medical and scientific information on several important topics. At this roundtable,

Fierce Pharma1d

FDA lays out stricter COVID vaccine policy in pivot from 'one-size-fits-all' approach

The FDA is tightening its regulatory policy around COVID vaccines with a new framework that raises the bar for certain approvals. | FDA Commissioner Marty Makary, M.D., and CBER head Vinay Prasad, M.D.

BioSpace3d

Makary’s ‘Conditional Approval’ Pathway for Rare Diseases Poses More Questions Than Answers

While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner Marty Makary’s proposal is light on details and raises potential concerns about safety,

1don MSN

Psychedelic stocks rise as FDA chief’s comments seen favorable to industry

Companies focused on psychedelic medicines traded higher for the second straight session on Tuesday after FDA Commissioner Marty Makary said evaluating the potential of psilocybin, MDMA, and other psychedelics will be a “top priority” under the Trump administration.